Atriva Therapeutics proceeds towards the clinic with virus replication inhibitor

Since its founding in 2015 by a leading team of viral research scientists in Germany, Atriva has progressed immensely with the development of a small molecule viral replication inhibitor. We announced our participation in its seed round of financing back in July 2017, and the participation of the co-lead investor High-Tech Gründerfonds in September of the same year.

Since then, their lead product ATR-002, a first-in-class inhibitor targeting host cell MEK, has completed preclinical development and a request for scientific advice has recently been filed at a European regulatory agency. Atriva plans to start its Phase 1 study in healthy volunteers in 2019. Atriva has just announced the first closing of its series A financing round, which provides them with capital to enter first-in-humans clinical testing.

InSynchrony Ventures is delighted to continue supporting the development of this novel and potentially broadly active therapy.

Click here to know more about Atriva’s recent development.

Click here for any questions regarding InSynchrony Ventures.